⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 13, 2024Open Access

Figure S1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma

Edgar Gonzalez‐Kozlova Hsin-Hui Huang Opeyemi A. Jagede Kevin Tuballes Diane M. Del Valle Geoffrey Kelly Manishkumar Patel Hui Xie Jocelyn Harris Kimberly Argueta Kai Nie Vanessa Barcessat Radim Moravec Jennifer Altreuter Dzifa Y. Duose Brad S. Kahl Stephen M. Ansell Joyce Yu Ethan Cerami James Lindsay Ignacio I. Wistuba Seunghee Kim‐Schulze Catherine Diefenbach Sacha Gnjatic

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Supplemental Figure 1. A. Volcano plots showing differentially expressed proteins with P<0.05 between treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gonzalez‐Kozlova et al. (2024) studied this question.

synapsesocial.com/papers/68e58a50b6db643587525f87 https://doi.org/10.1158/2767-9764.27016124

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma2024
2Figure S2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma2024
3Figure 1 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma2024
4Figure 3 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma2024
5Figure 4 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma2024

Data from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma2024
Figure 2 from Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma2024
Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma2024